NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Sarcomatrix Therapeutics Corp.

Sarcomatrix Therapeutics Corp.

Private
Reno, NevadaHealthcare & Life Scienceshttps://sarcomatrix.com/

Last Round

Seed

Aug 22, 2025

Est. Valuation

$14.25M

Total Funding Raised

$1.96M

Company Overview

Sarcomatrix Therapeutics Corp. is a biotechnology company that develops novel small-molecule therapeutics and protein replacement therapies for muscle-wasting diseases such as muscular dystrophy, sarcopenia, and cachexia.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoverymuscle-wasting diseasesmuscular dystrophysmall-molecule drugsprotein replacement therapyhigh-throughput screeningextracellular matrix biologyintegrin signalingbiotech startuppreclinical researchrare disease therapysarcopeniacachexiadrug pipelinebiopharma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Sarcomatrix Therapeutics Corp. Comparables

Compare Sarcomatrix Therapeutics Corp. with similar companies based on industry and business-model similarity.

Sarcomatrix Therapeutics Corp. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Strykagen Corp
89%
Epirium Bio
71%
Biophytis SA
71%

Sarcomatrix Therapeutics Corp. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedAug 22, 2025
CrowdfundingJul 8, 2024
GrantSep 20, 2023

Key People

Founding team and executive leadership

David Craig

Chief Executive Officer

Executive Team

David R. Craig

Chief Executive Officer

Executive Team

Sarcomatrix Therapeutics Corp. Investors

Notable investors and investment history

Sarcomatrix Therapeutics Corp. investors
InvestorRounds
National Institutes of Health (NIH)Grant

Sarcomatrix Therapeutics Corp. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Sarcomatrix Therapeutics Corp. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Sarcomatrix Therapeutics Corp.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersReno, Nevada
Employee Range4
Year Founded2022
Last FundingAug 22, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.